AbbVie partners with Iambic to deploy its AI molecular superintelligence platform, while Telix Pharmaceuticals agrees to acquire radioisotope leader ITM.
|Articles|June 4, 2008
Prix Galien USA - The Galen Prize - Gala Awards Ceremony
Prix Galien USA - The Galen Prize - Gala Awards Ceremony
Advertisement
Event Recap - Bio Pharma's Proudest Night
"...considered the industry's equivalent of the Nobel Prize..."
ThePrix Galien recognizes the technical, scientific and clinical researchskills necessary to develop innovative medicines .The Prix Galien wasinaugurated in the United States in September 2007 under the auspicesof an exceptional awards committee that includes 7 Nobel Laureates.
On September 24th, the second Prix Galien Awards ceremony took place indramatic fashion at the Museum of Natural History in New York City.
THE PRIX GALIEN USA 2008 WINNERS
VIEW THE WINNERS - VIDEO INTERVIEWS
Prix Galien
Dr. MacKay of Pfizer
Daria Hazuda of Merck
Dr. Bell of Alexion
Revlimid: Special Therapeutic Development
CONGRATULATORY MESSAGES
Advertisement
Related to this article
Novo Nordisk reports that CagriSema delivered 12.4% average weight loss in a late-stage diabetes trial, outperforming tirzepatide's 9.1% at comparable doses.
Inovalon's Jen Lamppa on how real-time clinical data feeds validate patient eligibility at enrollment — reducing burden while improving accuracy.
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
FDA approved Ultragenyx's Fayuvi (rebisufligene etisparvovec-hopf) as the first treatment for MPS IIIA Sanfilippo syndrome type A.
Former Rep. Joe Cunningham (D-SC), now spokesperson for the Pharmaceutical Reform Alliance, argues that codifying Most-Favored-Nation pricing into law is the real fix for drug costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Advertisement
Advertisement
Trending on PharmExec
1
CagriSema Tops Eli Lilly's Tirzepatide for Weight Loss in Late-Stage Diabetes Trial: Report
2
Understanding the Latest with MFN Pricing and What It Means to Pharma
3
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
4
The Battle to Own the GLP-1 Patient Journey
5